Saturday 17 October 2026
Export LMAT’s income statement to Excel — free account
LeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024. In the quarter to June 2026, revenue grew 9.57%, EPS grew 23.0%, free cash flow fell 28.0% and total debt was flat, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
80.82
2.34
−2.81%
Follow LMAT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
33.09 | 39.55 | 31.68 | 36.92 |
+8 more quarters Free account |
P/S ratio |
8.36 | 9.71 | 7.36 | 8.23 | |
P/FCF ratio |
29.72 | 31.47 | 24.66 | 29.95 | |
P/Operating CF |
137.39 | 164.92 | 79.28 | 68.94 | |
P/B ratio |
5.22 | 6.12 | 4.67 | 5.23 | |
Price to Tangible BV |
6.77 | 8.06 | 6.23 | 7.05 | |
EV/Sales |
7.58 | 8.95 | 6.60 | 7.52 | |
EV/EBITDA |
22.43 | 27.17 | 20.81 | 24.85 | |
EV/Operating CF |
23.97 | 26.27 | 20.29 | 24.72 | |
EV/FCF |
26.96 | 29.00 | 22.14 | 27.36 | |
Quick Ratio |
13.76 | 12.08 | 10.81 | 11.28 | |
Current Ratio |
16.31 | 14.32 | 12.89 | 13.58 | |
Net Debt/EBITDA |
(8.90) | (9.62) | (8.80) | (7.55) | |
Debt/Assets |
26.40% | 26.82% | 27.39% | 28.16% | |
Debt/Equity |
0.40 | 0.42 | 0.43 | 0.44 | |
Asset Turnover |
0.43 | 0.43 | 0.43 | 0.49 | |
Operating CF/Net income |
0.94 | 0.96 | 1.49 | 1.66 | |
Capex/Depreciation |
(0.80) | (0.98) | (0.63) | (0.81) | |
Interest Coverage |
15.67 | 13.67 | 14.51 | 15.66 | |
Research and Development Expense of Revenue |
6.89% | 6.10% | 5.48% | 4.87% | |
Selling, General and Administrative Expense of Revenue |
36.26% | 39.91% | 36.96% | 37.14% | |
Intangible Assets out of Total Assets |
0.15 | 0.16 | 0.16 | 0.16 | |
Share Based Compensation of Revenue |
2.75% | 3.14% | 3.25% | 2.85% | |
Graham Net Nets |
0.12 | 0.10 | 0.13 | 0.12 | |
Graham Number |
34.64 | 33.28 | 31.64 | 29.86 | |
Earnings Yield |
3.02% | 2.53% | 3.16% | 2.71% | |
Free Cash Flow Yield |
3.36% | 3.18% | 4.05% | 3.34% | |
Revenue per Share |
3.08 | 2.92 | 2.85 | 2.69 | |
Operating CF per Share |
0.70 | 0.66 | 1.02 | 1.27 | |
Capex per Share |
(0.10) | (0.12) | (0.08) | (0.10) | |
Free Cash Flow per Share |
0.60 | 0.54 | 0.94 | 1.17 | |
Cash per Share |
16.46 | 16.11 | 15.86 | 15.14 | |
Shareholders Equity per Share |
18.39 | 17.83 | 17.38 | 16.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.39 | 17.83 | 17.38 | 16.72 | |
Free Cash Flow |
13.65 | 12.31 | 21.38 | 26.48 | |
Working Capital |
458.36 | 444.45 | 431.91 | 418.74 | |
Capital Expenditures |
(2.31) | (2.78) | (1.78) | (2.28) | |
Net Current Asset Value |
268.09 | 254.92 | 246.06 | 232.88 | |
EV/EBIT |
25.73 | 31.40 | 24.27 | 29.25 | |
Capex to Sales |
0.03 | 0.04 | 0.03 | 0.04 | |
Price to Operating Income |
28.37 | 34.07 | 27.03 | 32.02 | |
| Other line items | |||||
Average Receivables |
36.11 | 35.44 | 31.84 | 32.34 | |
Average Payables |
4.08 | 3.18 | 2.70 | 2.56 | |
Average Inventory |
69.44 | 68.36 | 67.67 | 67.91 | |
Average Assets |
609.07 | 592.77 | 583.75 | 487.55 | |
Average Common Equity |
391.51 | 377.10 | 365.40 | 355.00 |
Columns are period end dates